medigraphic.com
ISSN 1665-2576 (Impreso)

2012, Número 2

<< Anterior Siguiente >>

Rev Mex Cir Endoscop 2012; 13 (2)


Obesidad mórbida, síndrome metabólico y cirugía bariátrica: Revisión de la literatura

Shiordia PJ, Ugalde VF, Cerón RF, Vázquez GA

Idioma: Español
Referencias bibliográficas: 49
Paginas: 85-94
Archivo PDF: 78.64 Kb.


RESUMEN

Este artículo es una revisión de la fisiopatología, epidemiología, costos, morbilidades, comorbilidades, mortalidad y evidencias sobre dos temas que hoy por hoy son obligados para los cirujanos, médicos internistas, endocrinólogos y nutriólogos por ser un problema de salud pública. La obesidad mórbida y la presencia de síndrome metabólico pueden ser tratados con éxito a través de la cirugía bariátrica y existe evidencia de que esto impacta positivamente el costo en los servicios de salud. Se revisan también las ventajas, desventajas, indicaciones, contraindicaciones y complicaciones de la cirugía bariátrica y los resultados de las técnicas más utilizadas actualmente.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Davis SN. Contemporary strategies for managing cardiometabolic risk factors. J Manag Care Pharm 2006; 12: 4-9.

  2. NCEP Expert Panel. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) . JAMA 2001; 285: 2486-97.

  3. Burns EM, Naseem H, Bottle A, Darzi A, Moorthy K. Introduction of laparoscopic bariatric surgery in England: observational population cohort study. BMJ 2010; 341: c 4296 doi:10.1136/bmj.c4296.

  4. Ashrafian H, le Roux CW, Darzi A, Athanasiou T. Effects of bariatric surgery on cardiovascular function. Circulation 2008; 118: 2091-102.

  5. Gómez R, Conde J, Gómez JJ. Las adipocinas: mediadores emergentes de la respuesta inmune y de la inflamación. Reumatol Clin 2009; 5: 6-12.

  6. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288-95.

  7. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care 2003; 26: 2442-50.

  8. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001; 7: 947-53.

  9. Otero M, Lago R, Gómez R, Dieguez C, Lago F, Gómez-Reino J et al. Towards a pro-inflammatory and immunomodulatory emerging role of leptin. Rheumatology (Oxford) 2006; 45: 944-50.

  10. Sánchez JC, López DF, Pinzón OA, Sepúlveda JC. Adipocinas y síndrome metabólico: múltiples facetas de un proceso fisiopatológico complejo. Rev Colomb Cardiol 2010; 17: 167-176.

  11. Nakazato M, Murakami N, Date Y et al. A role for ghrelin in the central regulation of feeding. Nature 2001; 409: 194-198.

  12. Wu JT, Kral JG. Ghrelin integrative neuroendocrine peptide in health and disease. Ann Surg 2004; 239: 464-474.

  13. Vague J. Sexual differentiation as a factor determining the forms of obesity. [La differénciation sexuelle, facteur determinant des formes del’obésité]. Presse Méd 1947; 55: 339-40.

  14. Wingard DL. Sex differences and coronary heart disease. A case of comparing apples and pears? Circulation 1990; 81: 1710-2.

  15. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000; 21: 697-738.

  16. Klein S, Fontana L, Young VL, Coggan AR, Kilo C, Patterson BW, Mohammed BS. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 2004; 350: 2549-57.

  17. Ridker PM, Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20-8.

  18. Lutz B. Molecular biology of cannabinoid receptors. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 123-142.

  19. Zarate A, Crestto M, Maiz A, Ravest G, Pino MI, Valdivia G, Moreno M, Villarroel L. Influence of obesity on health care costs and absenteeism among employees of a mining company. Rev Med Chil 2009; 137: 337-44.

  20. Colditz GA. Economic costs of obesity and inactivity. Med Sci Sports Exerc 1999; 31: 663-7.

  21. Thompson D, Wolf AM. The medical-care cost burden of obesity. Obes Rev 2001; 2: 189-97.

  22. Moreno O, Meoro A, Martínez A, Rodríguez C, Pardo C, Aznar S, López P, Serrano J, Boix E, Martin MD, Pico AAM. Comparison of two low-calorie diets: a prospective study of effectiveness and safety. J Endocrinol Invest 2006; 29: 633-40.

  23. O’Brien PE, Dixon JB. Adjustable gastric banding and conventional therapy for type 2 diabetes. A randomized controlled trial. JAMA 2008; 299: 316-323.

  24. González-González JJ, Sanz-Álvarez L, García-Bernardo C. Obesity in the history of surgery. Cir Esp 2008; 84: 188-95.

  25. Kremen AJ, Linner JH, Nelson CH. An experimental evaluation of the nutritional importance of proximal and distal small intestine. Ann Surg 1954; 140: 439-48.

  26. Scopinaro N, Papadia F, Camerini G, Marinari G, Civalleri D, Gian Franco A. A comparison of a personal series of biliopancreatic diversion and literature data on gastric bypass help to explain the mechanisms of resolution of type 2 diabetes by the two operations. Obes Surg 2008; 18: 1035-8.

  27. Hess DS, Hess DW, Oakley RS. The biliopancreatic diversion with the duodenal switch: results beyond 10 years. Obes Surg 2005; 15: 408-16.

  28. Rubin M, Yehoshua RT, Stein M, Lederfein D, Fichman S, Bernstine H, Eidelman LA. Laparoscopic sleeve gastrectomy with minimal morbidity. Early results in 120 morbidly obese patients. Obes Surg 2008; 18: 1567-70.

  29. Poires WJ. Bariatric surgery: risks and rewards. J Clin Endocrinol Metab 2008; 93: 89-96.

  30. Buchwald H, Estok R, Fahrbach K, Banel D, Sledge I. Trends in mortality in bariatric surgery: a systematic review and meta-analysis. Surgery 2007; 142: 632-5.

  31. van Dielen FM, Soeters PB, de Brauw LM, Greve JW. Laparoscopic adjustable gastric banding versus open vertical banded gastroplasty: a prospective randomized trial. Obes Surg 2005; 15: 1292-8.

  32. Evans RK, Bond DS, Demaria EJ, Wolfe LG, Meador JG, Kellum JM. Initiation and progression of physical activity after laparoscopic and open gastric bypass surgery. Surg Innov 2004; 11: 235-9.

  33. Serra J, Pérez N, Bou R, Bengochea M, Martínez R, Baltasar A. Gastrectomía tubular laparoscópica. Una operación bariátrica con diferentes indicaciones. Cir Esp 2006; 79: 289-92.

  34. Karmali S, Schauer P,Birch D, Sharma AM, Sherman V. Laparoscopic sleeve gastrectomy: an innovative new tool in the battle against the obesity epidemic in Canada. Can J Surg 2010; 53: 126-132.

  35. Karamanakos SN, Vagenas K, Kalfarentzos F et al. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. Ann Surg 2008; 247: 401-7.

  36. Monkhouse SJW, Morgan JDT, Norton SA. Complications of bariatric surgery: presentation and emergency management – a review. Ann R Coll Surg Engl 2009; 91: 280-286.

  37. Lalor PF, Tucker ON, Szomstein S. Complications after laparoscopic sleeve gastrectomy. J Surg Obes Relat Dis 2008; 4: 33-8.

  38. Chevallier JM. From bariatric to metabolic surgery: 15 years experience in a French university hospital. Bull Acad Natl Med. 2010; 194: 25-36; discussion 36-8.

  39. MacDonald KG, Long SD, Swanson MS, Brown BM, Morris P, Dohm GL, Pories WJ. The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus. J Gastrointest Surg 1997; 1: 213-20.

  40. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K. Bariatric surgery a systematic review and meta-analysis. JAMA 2004; 292: 1724-1737.

  41. Quesenberry CP Jr, Caan B, Jacobson A. Obesity, health services use, and health care costs among members of a health maintenance organization. Arch Intern Med 1998; 158: 466.72.

  42. Anderson LH, Martinson BC, Crain AL, Pronk NP, Whitebird RR, O’Connor PJ, Fine LJ. Health care charges associated with physical inactivity, overweight, and obesity. Prev Chronic Dis 2005; 2: A09.

  43. Zarate A, Crestto M, Maiz A, Ravest G, Pino MI, Valdivia G, Moreno M, Villarroel L. Influence of obesity on health care costs and absenteeism among employees of a mining company. Rev Med Chil 2009; 137: 337-44.

  44. Tsai SP, Ahmed FS, Wendt JK, Bhojani F, Donnelly RP. The impact of obesity on illness absence and productivity in an industrial population of petrochemical workers. Ann Epidemiol 2008; 18: 8-14.

  45. Keating CL, Dixon JB, Moodie ML, Peeters A, Bulfone L, Maglianno DJ, O’Brien PE. Cost-effectiveness of surgically induced weight loss for the management of type 2 diabetes: modeled lifetime analysis. Diabetes Care 2009; 32: 567-74.

  46. Cremieux PY, Buchwald H, Shikora SA, Ghosh A, Yang HE, Buessing M. A study on the economic impact of bariatric surgery. Am J Manag Care 2008; 14: 589-96.

  47. Picot J, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L, Clegg AJ. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess 2009; 13: 1-190, 215-357.

  48. Lujan JA, Parrilla P. Selection of candidates for bariatric surgery [Selección del paciente candidato a cirugía bariátrica y preparación preoperatoria]. Cir Esp 2004; 75: 232-5.

  49. Christou NV, Efthimiou E. Bariatric surgery waiting times in Canada. Can J Surg 2009; 52: 229-34.




2020     |     www.medigraphic.com